1. Home
  2. Directory
  3. Colorado
  4. Aurora
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1912090366

ARCHANA SHRESTHA MD
Prescription History 1912090366
Psychiatry & Neurology - Epilepsy in Aurora, CO


Quality Rating: 91.11 out of 100 score

NPI Status: Active since September 30, 2006

Contact Information

12605 E 16TH AVE
AURORA, CO
ZIP 80045
Phone: (720) 848-0000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ARCHANA SHRESTHA MD, an active Epilepsy specialist practicing in Aurora, CO. Our medical registry currently tracks 9 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 210 documented patient claims. Among these therapy options, the most frequently utilized medication is Clobazam, which accounts for 34 claims alone.

Medication Index

Briviact

Generic Formulation: BrivaracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 16
30-Day Fills 38.7
Days Supply 1,160
CO State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills30.5
Peer Average Days Supply869
Conservative Utilization

This provider writes prescriptions for this formulation 38.5% less frequently than the standard regional baseline metric for practitioners inside CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $48,638.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,039.88

State Avg Cost Per Claim

$1,674.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Brivaracetam is used to treat seizures (epilepsy).

Clobazam

Generic Formulation: ClobazamSpecialty: Neurology
Provider Metrics Summary
Total Claims 34
30-Day Fills 48.7
Days Supply 1,462
CO State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills37.9
Peer Average Days Supply1,105
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,586.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$399.60

State Avg Cost Per Claim

$300.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.

Therapeutic Applications

This medication is used with other medications to help control seizures. It belongs to a class of medications called benzodiazepines, which act on the brain and nerves (central nervous system) to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).

Lacosamide

Generic Formulation: LacosamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 25
30-Day Fills 45.0
Days Supply 1,339
CO State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills37.5
Peer Average Days Supply1,054
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,979.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$679.17

State Avg Cost Per Claim

$342.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Therapeutic Applications

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Lamotrigine

Generic Formulation: LamotrigineSpecialty: Neurology
Provider Metrics Summary
Total Claims 34
30-Day Fills 87.9
Days Supply 2,637
CO State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills70.6
Peer Average Days Supply2,061
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,071.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.52

State Avg Cost Per Claim

$20.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER.

Therapeutic Applications

Lamotrigine is used alone or with other medications to prevent and control seizures. It may also be used to help prevent the extreme mood swings of bipolar disorder in adults. Lamotrigine is known as an anticonvulsant or antiepileptic drug. It is thought to work by restoring the balance of certain natural substances in the brain. This drug is not approved for use in children younger than 2 years due to an increased risk of side effects (such as infections).

Lamotrigine Er

Generic Formulation: LamotrigineSpecialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 19.6
Days Supply 588
CO State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills32.3
Peer Average Days Supply948
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,614.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$634.58

State Avg Cost Per Claim

$430.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER.

Therapeutic Applications

Lamotrigine is used alone or with other medications to prevent and control seizures. It may also be used to help prevent the extreme mood swings of bipolar disorder in adults. Lamotrigine is known as an anticonvulsant or antiepileptic drug. It is thought to work by restoring the balance of certain natural substances in the brain. This drug is not approved for use in children younger than 2 years due to an increased risk of side effects (such as infections).

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 31
30-Day Fills 66.5
Days Supply 1,995
CO State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills60.7
Peer Average Days Supply1,740
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,805.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$90.52

State Avg Cost Per Claim

$46.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Phenytoin Sodium Extended

Generic Formulation: Phenytoin Sodium ExtendedSpecialty: Neurology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
CO State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills25.7
Peer Average Days Supply725
Conservative Utilization

This provider writes prescriptions for this formulation 35.3% less frequently than the standard regional baseline metric for practitioners inside CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $642.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$58.43

State Avg Cost Per Claim

$38.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Phenytoin is used to prevent and control seizures (also called an anticonvulsant or antiepileptic drug). It works by reducing the spread of seizure activity in the brain.

Xcopri

Generic Formulation: CenobamateSpecialty: Neurology
Provider Metrics Summary
Total Claims 23
30-Day Fills 29.0
Days Supply 860
CO State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills31.0
Peer Average Days Supply908
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $34,607.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,504.69

State Avg Cost Per Claim

$1,448.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of seizure disorder (partial onset). It is not known exactly how it works, but it may affect the action of some nerves that cause seizures.

Zonisamide

Generic Formulation: ZonisamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 24
30-Day Fills 52.7
Days Supply 1,580
CO State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills46.9
Peer Average Days Supply1,381
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,086.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$45.27

State Avg Cost Per Claim

$52.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.

Therapeutic Applications

Zonisamide is used with other medications to prevent and control seizures (epilepsy). Zonisamide is a sulfonamide anticonvulsant and a carbonic anhydrase inhibitor. It is unknown how zonisamide works to prevent seizures.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ARCHANA SHRESTHA MD provides transparency into local medical care patterns within Aurora, CO.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Epilepsy ** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.